Lexicon Stock Insiders

LXRX
 Stock
  

USD 2.13  0.09  4.05%   

Lexicon Pharmaceutcl employes about 87 people. The company is managed by 18 executives with total tenure of roughly 196 years, averaging almost 10.0 years of service per executive having 4.83 employees per reported executive. Break down of Lexicon Pharmaceutcl management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Lexicon Pharmaceutcl future performance.
Additionally, see Correlation Analysis.
  
  Lonnel Coats  CEO
CEO and President and Director
  Raymond Debbane  Chairman
Independent Chairman of the Board
  Praveen Tyle  President
Executive Vice President of Research and Development

Lexicon Pharmaceutcl Return on Sales

(299.48)

Lexicon Pharmaceutcl Management Team Effectiveness

Lexicon Pharmaceutcl has return on total asset (ROA) of (32.9) % which means that it has lost $32.9 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (69.18) %, meaning that it created substantial loss on money invested by shareholders. Lexicon Pharmaceutcl management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -66.73 in 2022. Return on Average Assets is likely to drop to -52.87 in 2022. Lexicon Pharmaceutcl Tangible Asset Value is fairly stable at the moment as compared to the past year. Lexicon Pharmaceutcl reported Tangible Asset Value of 92.37 Million in 2021
Issuance Purchase of Equity Shares is likely to rise to about 37.7 M in 2022, whereas Weighted Average Shares is likely to drop slightly above 115 M in 2022.

Lexicon Pharmaceutcl Workforce Comparison

Lexicon Pharmaceutcl is rated third overall in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 14,902. Lexicon Pharmaceutcl maintains roughly 87.0 in number of employees contributing less than 1% to stocks in Biotechnology industry.

Lexicon Pharmaceutcl Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lexicon Pharmaceutcl insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lexicon Pharmaceutcl's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Lexicon Pharmaceutcl insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Lexicon Pharmaceutcl Benchmark Summation

The output start index for this execution was eight with a total number of output elements of fifty-three. The Lowest value over a specified period line plots minimum value of Lexicon Pharmaceutcl price series.
.

Lexicon Pharmaceutcl Notable Stakeholders

A Lexicon Pharmaceutcl stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Lexicon Pharmaceutcl often face trade-offs trying to please all of them. Lexicon Pharmaceutcl's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Lexicon Pharmaceutcl's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Lonnel Coats - CEO and President and DirectorProfile
Raymond Debbane - Independent Chairman of the BoardProfile
Praveen Tyle - Executive Vice President of Research and DevelopmentProfile
Gary Branch - Vice President - SalesProfile
Pablo Lapuerta - Executive Vice President - Clinical Development, Chief Medical OfficerProfile
James Tessmer - Vice President - Finance & AccountingProfile
Jeffrey Wade - CFO, Executive Vice President - Corporate DevelopmentProfile
Kiernan Seth - Vice President - MarketingProfile
Alan Main - Executive VP of CMC and Supply OperationsProfile
Samuel Barker - Independent DirectorProfile
Robert Lefkowitz - Independent DirectorProfile
Christopher Sobecki - Independent DirectorProfile
Alan Nies - Independent DirectorProfile
Frank Palantoni - Independent DirectorProfile
Judith Swain - Independent DirectorProfile
Philippe Amouyal - Independent DirectorProfile
John Northcott - VP of Marketing, Commercial Strategy and OperationsProfile
Alexander Santini - Chief Commercial OfficerProfile

About Lexicon Pharmaceutcl Management Performance

The success or failure of an entity such as Lexicon Pharmaceutcl often depends on how effective the management is. Lexicon Pharmaceutcl management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Lexicon management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Lexicon management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2022
Return on Investment(61.85) (66.73) 
Return on Average Assets(51.52) (52.87) 
Return on Average Equity(65.01) (70.14) 
Return on Invested Capital(5.88) (6.04) 
Return on Sales(291.80) (299.48) 
The data published in Lexicon Pharmaceutcl's official financial statements usually reflect Lexicon Pharmaceutcl's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Lexicon Pharmaceutcl. For example, before you start analyzing numbers published by Lexicon accountants, it's critical to develop an understanding of what Lexicon Pharmaceutcl's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Lexicon Pharmaceutcl's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lexicon Pharmaceutcl's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Lexicon Pharmaceutcl's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lexicon Pharmaceutcl. Please utilize our Beneish M Score to check the likelihood of Lexicon Pharmaceutcl's management to manipulate its earnings.

Lexicon Pharmaceutcl Workforce Analysis

Traditionally, organizations such as Lexicon Pharmaceutcl use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Lexicon Pharmaceutcl within its industry.

Lexicon Pharmaceutcl Manpower Efficiency

Return on Lexicon Pharmaceutcl Manpower

Revenue Per Employee3.5 K
Revenue Per Executive6.9 K
Net Loss Per Employee1.1 M
Net Loss Per Executive5.4 M
Working Capital Per Employee1.6 M
Working Capital Per Executive7.8 M
Today, most investors in Lexicon Pharmaceutcl Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lexicon Pharmaceutcl's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lexicon Pharmaceutcl per employee as a starting point in their analysis.

Per Employee

Lexicon Pharmaceutcl Per Employee Growth Over Time

Net Income Per Employee

(1.09 Million)

Lexicon Pharmaceutcl Net Income Per Employee is fairly stable at the moment as compared to the past year. Lexicon Pharmaceutcl reported Net Income Per Employee of (1.01 Million) in 2021

Revenue Per Employee

3,515.13

Lexicon Pharmaceutcl Revenue Per Employee is fairly stable at the moment as compared to the past year. Lexicon Pharmaceutcl reported Revenue Per Employee of 3,425 in 2021
Additionally, see Correlation Analysis. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for analysis

When running Lexicon Pharmaceutcl price analysis, check to measure Lexicon Pharmaceutcl's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceutcl is operating at the current time. Most of Lexicon Pharmaceutcl's value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceutcl's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lexicon Pharmaceutcl's price. Additionally, you may evaluate how the addition of Lexicon Pharmaceutcl to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Is Lexicon Pharmaceutcl's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceutcl. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceutcl listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
(0.63) 
Market Capitalization
402 M
Quarterly Revenue Growth YOY
0.7
Return On Assets
(0.33) 
Return On Equity
(0.69) 
The market value of Lexicon Pharmaceutcl is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceutcl's value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceutcl's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceutcl's market value can be influenced by many factors that don't directly affect Lexicon Pharmaceutcl's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceutcl's value and its price as these two are different measures arrived at by different means. Investors typically determine Lexicon Pharmaceutcl value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceutcl's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.